Cancer centers are re-evaluating their relationships with health care companies, including when, if ever, doctors and researchers should serve on corporate boards. Here are some hospital executives and cancer researchers who sit on the boards of publicly traded companies, in dual roles that may raise questions about conflicts of interest.
Dr. Laurie H. Glimcher
President and chief executive of the Dana-Farber Cancer Institute, Boston
Company: Dr. Glimcher sits on the boards of the British drugmaker GlaxoSmithKline and Waters Corp., a laboratory equipment and software company.
Outside Compensation: Dr. Glimcher joined the board of GlaxoSmithKline in September of 2017; she received $101,000 in total compensation from the company that year, plus compensation of $285,440 from Waters that year.
Dr. Gary Gilliland
President and director of the Fred Hutchinson Cancer Research Center, Seattle
Company: Dr. Gilliland serves on the board of LabCorp, a blood testing company.
Outside Compensation: Dr. Gilliland received $269,948 in cash and stock from LabCorp in 2017.
Mary C. Beckerle
Chief executive of the Huntsman Cancer Institute at the University of Utah, Salt Lake City
Company: Dr. Beckerle is on the board of the health care giant Johnson & Johnson and the Huntsman Corporation, a chemical manufacturer.
Compensation: Johnson & Johnson paid Dr. Beckerle $324,893 in total compensation in 2017, and the Huntsman Corporation paid her $310,000.
Dr. Craig B. Thompson
Chief executive of Memorial Sloan Kettering Cancer Center, New York
Company: Dr. Thompson resigned in October from the boards of the drug maker Merck and of Charles River Laboratories, which assists in early research.
Outside Compensation: In 2017, Dr. Thompson received $300,000 in compensation from Merck. He received $285,050 in cash and company stock from Charles River in 2017.
Deputy director for core technologies of the Sloan Kettering Institute, the research arm of Memorial Sloan Kettering Cancer Center, New York
Company: President, chief executive and chief scientific officer at AngioGenex, a tiny, publicly traded biotech.
Outside Compensation: He took no salary from AngioGenex in 2017, but he owns nearly 9 percent of the company in stock or stock options.
Dr. Charles L. Sawyers
Chair of the human oncology and pathogenesis program at Memorial Sloan Kettering Cancer Center, New York
Company: Member of the board of Novartis, the Swiss pharmaceutical company. Founder of several companies, including ORIC Pharmaceuticals, a private cancer start-up. (His salary at Memorial Sloan Kettering is paid by the Howard Hughes Medical Institute.)
Outside Compensation: Dr. Sawyers received total compensation in 2017 of about $360,000 from Novartis.
SOURCE: COMPANY FILINGS; EQUILAR.